“We are very fortunate to have David Moore join us”, said Neil Belenkie, Chief Executive Officer of Sirona Biochem. “David’s previous experience and success in the USA leading many of the tasks that we are about to undertake, are unique and invaluable resources to Sirona’s leadership team. With David on board, we gain another level of confidence in our ability to execute our strategy”.
About David Moore
David joins the board of directors with significant biotech and big pharma experience. David is currently Chief Commercial Officer of Cempra, a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Prior to joining Cempra, David was Chief Business Officer of Ocera Therapeutics, a publicly traded clinical stage biotech focused in advanced liver disease. Prior to Ocera, he was Chief Business Officer of Tranzyme Pharma, a publicly traded clinical stage biotech and macrocyclic discovery chemistry company which David and the management team successfully merged with Ocera Therapeutics in July 2013. David has participated in several rounds of corporate financing, successfully negotiated multiple license deals for both clinical stage products and pre-clinical compounds in addition to the recent strategic merger process. David has an extensive commercial background having spent over 15 years developing and managing pharmaceutical commercial programs with the majority of that time spent with Ortho-McNeil and Janssen divisions of Johnson & Johnson. David received his B.Sc. in Biology from Towson University and an M.B.A. from Lehigh University, and a second graduate degree in Health Policy Excellence from Thomas Jefferson University.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements.